SCTX — Scribe Therapeutics
Median target
$55
calls from the last 12 months
Implied return
+71.1%
median target vs. price
Coverage
4 analysts · 4 calls
updated in the last 12 months
Consensus
4/0/0+4 net
Buy / Hold / Sell
Which analysts are behind SCTX's consensus?
See every current rating, price target and the analysts' track records for Scribe Therapeutics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 4 analysts with calls on SCTX updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
SCTX elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-07-28 | Insiders | Aghazadeh Behzad +2Director | Insider purchase | 7.9K sh @ $18.25 | $144K |
| 2026-07-27 | Insiders | Gordon Carl LDirector | Insider purchase | 1.0M sh @ $15.00 | $15.0M |
| 2026-07-27 | Insiders | Orbimed Advisors Llc +1Director | Insider purchase | 1.0M sh @ $15.00 | $15.0M |
| 2026-07-27 | Insiders | Ah Bio Fund Ii, L.P. +510% owner | Insider purchase | 333.3K sh @ $15.00 | $5.0M |
| 2026-07-24 | Insiders | Aghazadeh Behzad +2Director | Insider purchase | 2.3M sh @ $15.00 | $35.0M |
| 2026-07-24 | Insiders | Aghazadeh Behzad +2Director | Insider purchase | 50.0K sh @ $22.31 | $1.1M |
| 2026-07-23 | Insiders | Lucas SvetlanaChief Business Officer | Insider purchase | 3.0K sh @ $15.00 | $45K |
| 2026-07-23 | Insiders | Parrot DavidChief Financial Officer | Insider purchase | 1.3K sh @ $15.00 | $20K |
| 2026-07-23 | Insiders | Parrot DavidChief Financial Officer | Insider purchase | 1.3K sh @ $15.00 | $20K |
More: insider activity · executive branch · trending